Prelude Therapeutics Inc (PRLD)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $81k
- Apr 6 · Unusual
- Form 4 sales
- 28
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualAug 25 2021
Sold 8,333 shares at $33.34 ($278k)
Piper Brian, Chief Financial Officer
Sold 100% of holdings ($278k position)0 shares leftFiling
- 2 Form 4 salePlan not statedAug 27 +2 days
Sold 7,714 shares at $35.75 ($276k)
Scherle Peggy, Chief Scientific Officer
Sold 4.3% of holdings ($6.5M position)172,920 shares left0.8x usual sizeFiling
- 3 Form 4 saleUnusualSep 2 +6 days
Sold 17,000 shares at $41.68 ($709k)
Pierce Christopher, EVP and Chief of Business Oper
Sold 81.9% of holdings ($865k position)3,750 shares left20.5x usual sizeFiling
- 4 Form 4 saleUnusualSep 7 +5 days
Sold 15,000 shares at $36.68 ($550k)
Mauro David J, Chief Medical Officer
Sold 100% of holdings ($550k position)0 shares left1x usual sizeFiling
- 5 Form 4 saleUnusualOct 5 +28 days
Sold 15,000 shares at $30.96 ($464k)
Mauro David J, Chief Medical Officer
Sold 100% of holdings ($464k position)0 shares left1x usual sizeFiling
- 6 Form 4 saleUnusualNov 16 +42 days
Sold 28,751 shares at $15.88 ($457k)
Morosini Deborah, EVP, Chief of Clinical Affairs
Sold 98.5% of holdings ($464k position)444 shares left28.8x usual sizeFiling
- 7 Form 4 saleUnusualDec 15 +29 days
Sold 28,751 shares at $13.00 ($374k)
Morosini Deborah, EVP, Chief of Clinical Affairs
Sold 98.5% of holdings ($380k position)444 shares left13.6x usual sizeFiling
- 8 Form 4 saleUnusualApr 6 +477 days
Sold 13,280 shares at $6.12 ($81k)
Huang Jane, President, CMO
No 10b5-1 planSold 35.4% of holdings ($230k position)24,220 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (28)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | Huang Jane | President, CMO | Form 4 sale | 13,280 | $81k | 35.4% | Unusual | SEC |
| Dec 15, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Form 4 sale | 28,751 | $374k | 98.5% | Unusual | SEC |
| Nov 16, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Form 4 sale | 28,751 | $457k | 98.5% | Unusual | SEC |
| Oct 5, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $464k | 100.0% | Unusual | SEC |
| Sep 7, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $550k | 100.0% | Unusual | SEC |
| Sep 2, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Form 4 sale | 17,000 | $709k | 81.9% | Unusual | SEC |
| Aug 27, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 7,714 | $276k | 4.3% | Plan not stated | SEC |
| Aug 25, 2021 | Piper Brian | Chief Financial Officer | Form 4 sale | 8,333 | $278k | 100.0% | Unusual | SEC |
| Aug 13, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 2,286 | $80k | 1.3% | Plan not stated | SEC |
| Aug 5, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $466k | 100.0% | Unusual | SEC |
| Jul 27, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 20,000 | $709k | 10.4% | Plan not stated | SEC |
| Jul 6, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $412k | 100.0% | Unusual | SEC |
| Jun 7, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $487k | 100.0% | Unusual | SEC |
| May 25, 2021 | Piper Brian | Chief Financial Officer | Form 4 sale | 8,333 | $286k | 100.0% | Unusual | SEC |
| May 7, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 10,000 | $408k | 5.5% | Plan not stated | SEC |
| May 5, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,000 | $602k | 100.0% | Unusual | SEC |
| Apr 29, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Form 4 sale | 3,295 | $133k | 46.8% | Unusual | SEC |
| Apr 29, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Form 4 sale | 3,223 | $130k | 87.9% | Unusual | SEC |
| Apr 27, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 25,000 | $885k | 100.0% | Unusual | SEC |
| Apr 19, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 25,000 | $772k | 100.0% | Unusual | SEC |
| Apr 8, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 4,630 | $178k | 2.6% | Plan not stated | SEC |
| Apr 8, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Form 4 sale | 200 | $8k | 5.1% | Plan not stated | SEC |
| Apr 8, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Form 4 sale | 100 | $4k | 18.4% | Plan not stated | SEC |
| Apr 8, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 9,617 | $369k | 100.0% | Unusual | SEC |
| Apr 7, 2021 | Scherle Peggy | Chief Scientific Officer | Form 4 sale | 15,370 | $604k | 8.2% | Plan not stated | SEC |
| Apr 7, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Form 4 sale | 828 | $33k | 18.1% | Plan not stated | SEC |
| Apr 7, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Form 4 sale | 1,000 | $40k | 69.3% | Unusual | SEC |
| Apr 7, 2021 | Mauro David J | Chief Medical Officer | Form 4 sale | 15,383 | $605k | 100.0% | Unusual | SEC |